Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Recent & Breaking News (NDAQ:ONCT)

Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020

Business Wire September 21, 2020

Oncternal Therapeutics to Participate in September Investor Conferences

Business Wire September 10, 2020

Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 Million

Business Wire August 27, 2020

Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering

Business Wire August 27, 2020

Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results

Business Wire August 6, 2020

Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update

Business Wire July 30, 2020

Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma

Business Wire July 27, 2020

Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Business Wire July 20, 2020

Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia

Business Wire June 30, 2020

Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma

Business Wire June 30, 2020

Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Business Wire May 20, 2020

Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting

Business Wire May 19, 2020

Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results

Business Wire May 7, 2020

Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update

Business Wire May 5, 2020

Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update

Business Wire May 1, 2020

Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results

Business Wire March 16, 2020

Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update

Business Wire March 11, 2020

Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma

Business Wire March 11, 2020

Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Business Wire February 6, 2020

Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium

Business Wire December 12, 2019